HAMBURG, Sept. 6, 2011 /CNW/ - Indivumed is pleased to announce that
Helge Bastian, Ph.D, will join Indivumed as Managing Director and Chief
Commercial Officer on September 12, 2011.
Hartmut Juhl, founder and CEO of Indivumed, says: "The board and me
personally are proud to have Dr. Bastian with Indivumed today. His
tremendous background, global expertise and leadership experience will
support the further development of our company."
Dr. Bastian has over 19 years of international leadership experience in
corporations serving the molecular biology, life science research,
diagnostics, biotechnology, drug development and pharmaceutical
manufacturing industry. Previously, Dr. Bastian was Vice President of
Global Marketing, Business Development & Strategy for the Research
Biotech business unit and member of the leadership team at
Sigma-Aldrich in St. Louis, USA.
He worked as Executive Vice President of Life Science Services business
unit and member of Senior Executive Management Team at SGS in Geneva,
Switzerland. Dr. Bastian joined SGS after more than eleven years with
QIAGEN in Duesseldorf, Germany, where he held various management
positions, most recently as Vice President Molecular Diagnostics, Vice
President Global Strategic Marketing, Vice President PreAnalytix and
member of executive steering committee.
Dr. Bastian holds a diploma in biology (focus area of biochemistry) and
a Ph.D. in molecular biology. He is an alumnus from the
Max-Planck-Network and the Columbia Business School.
"Quickly translating new molecular discoveries into medical practice to
improve the diagnosis and treatment of diseases that are
life-threatening, such as cancer, is an absolute necessity and
addresses a genuine demand," Dr. Bastian explains his decision to join
Indivumed. "As a strong believer in personalized medicine approaches, I
am extremely intrigued by Indivumed's approach to improve cancer
research and drug development, and I am excited about having the
opportunity to further expand the Indivumed product and service
Indivumed GmbH was founded in 2002 and maintains the world's leading
tumor database and high-quality biobank for the development of new
cancer diagnostics and therapies. The biotechnology company provides a
unique research infrastructure through collaboration with clinics,
oncology networks and special technologies and is recognized by
numerous pharmaceutical companies and leading academic institutions as
a quality-focused research partner and service provider. With an
extraordinary collection of biological samples taken from more than
13,000 cancer patients, Indivumed provides research services such as
immunohistochemical screening, profiling of new anti-cancer agents on
viable primary tumor tissues, a wide range of biospecimen formats taken
from Indivumed's own biobank and other research services with a focus
on analyzing pathways relevant to cancer and new targeted therapeutics.
In 2008, Indivumed, together with scientists from the John Hopkins
University in Baltimore, founded Inostics GmbH, a biotech company that
specializes in DNA diagnostics.
Indivumed has its main office in Hamburg and a subsidiary, Indivumed
Inc., in Kensington, Maryland, USA. For more information, please visit http://www.indivumed.com.
SOURCE Indivumed GmbH
For further information:
Vice President Marketing & Sales